Can fatty liver disease be reversed?

Unlike many chronic diseases, fatty liver disease, particularly at its early stages, has a valuable feature: it's often reversible.

The liver has an exceptional capacity for regeneration. It is the only organ in the human body able to regrow almost entirely after part of its volume is removed. This ability explains why it can shed accumulated fat, and even, to some extent, repair early fibrosis, once the causes of the damage subside.

A rare piece of good news in chronic disease

At its simple stage, before inflammation or fibrosis appears, fatty liver disease can regress in just a few months through appropriate lifestyle changes. This is a notable difference from many other chronic diseases, where the goal is often limited to slowing progression rather than genuinely reversing the situation.

Different types of liver damage don't regress at the same pace. The fat itself decreases quickly: imaging studies show a measurable drop within just a few weeks of reduced intake. Inflammation, in steatohepatitis, generally takes several months. Fibrosis is the slowest to regress and can require one to several years of sustained effort. Established cirrhosis generally doesn't disappear, but its progression can be slowed and its complications reduced, which is why catching the disease before this stage matters.

The central role of diet

Reducing intake of refined sugars and fructose, found in large amounts in many processed foods and sugary drinks, plays a particularly important role in reducing liver fat, even more so than overall calorie reduction alone. A Mediterranean-style diet, rich in fiber, vegetables, and unsaturated fats, is regularly associated with measurable improvement.

Fructose has a specific feature that explains its role. Unlike glucose, which every organ uses, it is processed almost exclusively by the liver, which readily converts it to fat when it arrives in excess. Fructose from whole fruit poses little problem, since it arrives in small amounts, accompanied by fiber and water that slow its absorption. Soda, fruit juice, even “100% pure juice,” and products containing glucose-fructose syrup, on the other hand, deliver large amounts all at once. Replacing sugary drinks with water is often the single change with the biggest effect for the least effort.

A Mediterranean-style diet is the top recommendation in the 2024 European guidelines. In practice, this means favoring vegetables, legumes, whole grains, whole fruit, fish, nuts, and olive oil, while limiting red meat, processed meat, and ultra-processed foods. It improves liver fat even without substantial weight loss.

Two other points are worth knowing. Unsweetened coffee is associated in numerous studies with a lower risk of fibrosis, starting at two to three cups a day. The mechanism isn't fully understood, but the data are consistent enough that professional societies mention it. Conversely, alcohol adds its own toxic effects to those of metabolism, even at levels considered moderate. With advanced fibrosis, abstinence is recommended. The hub's Is my alcohol consumption risky? test can help assess this.

Modest weight loss, a real effect

As with other metabolic complications, there's no need to aim for radical weight loss. A reduction of 7% to 10% of starting weight is generally enough to significantly improve fatty liver disease, or even resolve it in some early-stage cases.

A landmark Cuban study, published in 2015 in Gastroenterology (Vilar-Gomez et al.), followed nearly 300 people with biopsy-confirmed steatohepatitis over a year of lifestyle changes. It pinned down these thresholds. A loss of at least 5% of body weight reduced liver fat. Beyond 7%, steatohepatitis resolved in a majority of patients. Beyond 10%, it resolved in 90% of them, and fibrosis regressed in nearly half. For someone weighing 200 pounds, 10% represents 20 pounds — a demanding but realistic target over a year.

Speed matters too. Very rapid weight loss, beyond about a pound a week sustained over time, can paradoxically worsen liver inflammation, as it suddenly releases a lot of fat into the bloodstream. A gradual, lasting loss is better than a drastic diet followed by weight regain.

For people with severe obesity, bariatric surgery leads to regression of steatohepatitis and fibrosis in a large majority of operated patients. It is discussed case by case with a specialized team. The hub's Am I overweight/obese? tool helps place your BMI and waist circumference.

Physical activity, independent of weight

Regular physical activity improves fatty liver disease even without significant weight loss. It acts directly on insulin sensitivity and on fat metabolism in the liver, one more reason not to reduce this effort to a question of weight alone.

Active muscles consume glucose and fat, which relieves the liver. They also become more sensitive to insulin, which reduces the flow of fat toward the liver. Studies show a reduction in liver fat on the order of 20% to 30% within a few months of training, even when weight changes little.

The European guidelines recommend 150 to 300 minutes a week of moderate-intensity activity, such as brisk walking, cycling, or swimming, or 75 to 150 minutes of vigorous activity. Both endurance and strength training appear effective, which allows you to choose based on your preferences and abilities. Reducing time spent sitting matters too. The hub's What is my level of sedentary behavior/physical activity? tool helps assess your starting point. Finally, sufficient, good-quality sleep contributes to metabolic balance: lack of sleep and untreated sleep apnea promote insulin resistance.

The first medications, reserved for advanced forms

For a long time, no medication was approved to treat fatty liver disease. That has been changing since 2024.

Resmetirom was the first medication approved specifically for this disease, in the United States in 2024, then in the European Union in August 2025, under conditional approval. It acts on a thyroid hormone receptor present in the liver, which stimulates fat burning. In France, the Haute Autorité de santé issued a favorable opinion on its reimbursement in April 2026. It is reserved for adults with steatohepatitis and moderate-to- advanced fibrosis (stages F2 to F3), without cirrhosis. The HAS, however, judged that it didn't offer an improvement over current care, pending longer-term data on its clinical benefit and tolerability. Semaglutide, already used for diabetes and obesity, was also approved for this use in the United States in 2025 and in the United Kingdom in 2026, after a trial showing steatohepatitis resolved in about 63% of treated patients, versus 34% on placebo.

These treatments concern only a minority of patients, those with significant fibrosis, and add to lifestyle measures without replacing them. For the vast majority of people with simple steatosis, care still relies first and foremost on the lifestyle changes described above. Treatment of any already present metabolic risk factors (diabetes, hypertension, cholesterol) adds to this. Certain diabetes medications, in fact, have a beneficial effect on the liver, which the doctor can factor into their choices.

What to remember

Contrary to what a “liver disease” diagnosis might suggest, early-stage fatty liver disease isn't a fixed trajectory. It's one of the rare areas where modest but sustained lifestyle changes can genuinely reverse the situation, rather than just slow its progression.

Consistency matters more than intensity. A few changes maintained over time are worth more than an intense effort for a few weeks. Repeating the FIB-4 calculation at subsequent blood panels, with your doctor's input, makes it possible to track progress.

To estimate your own risk level, take the “Do I have fatty liver disease?” test.